2/26/2014 8:13:23 AM
This morning Eli Lilly & Co . (LLY) released top-line results for the sixth AWARD study for their once-weekly GLP-1 dulaglutide. According to a company issued press release; “In the AWARD-6 study, once-weekly dulaglutide 1.5 mg achieved the primary endpoint of non-inferiority to once-daily liraglutide 1.8 mg, as measured by the reduction of hemoglobin A1c (HbA1c) from baseline at 26 weeks.”
Help employers find you! Check out all the jobs and post your resume.
comments powered by